The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review
- PMID: 31484576
- PMCID: PMC6727531
- DOI: 10.1186/s13054-019-2562-y
The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review
Erratum in
-
Correction to: The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review.Crit Care. 2020 Jan 3;24(1):3. doi: 10.1186/s13054-019-2699-8. Crit Care. 2020. PMID: 31900202 Free PMC article.
Abstract
Background: The effect of premorbid β-blocker exposure on clinical outcomes in patients with sepsis is not well characterized. We aimed to examine the association between premorbid β-blocker exposure and mortality in sepsis.
Methods: EMBase, MEDLINE, and Cochrane databases were searched for all studies of premorbid β-blocker and sepsis. The search was last updated on 22 June 2019. Two reviewers independently assessed, selected, and abstracted data from studies reporting chronic β-blocker use prior to sepsis and mortality. Main data extracted were premorbid β-blocker exposure, mortality, study design, and patient data. Two reviewers independently assessed the risk of bias and quality of evidence.
Results: In total, nine studies comprising 56,414 patients with sepsis including 6576 patients with premorbid exposure to β-blockers were eligible. For the primary outcome of mortality, two retrospective studies reported adjusted odds ratios showing a reduction in mortality with premorbid β-blocker exposure. One study showed that premorbid β-blocker exposure decreases mortality in patients with septic shock. Another study showed that continued β-blockade during sepsis is associated with decreased mortality.
Conclusion: This systematic review suggests that β-blocker exposure prior to sepsis is associated with reduced mortality. There was insufficient data to conduct a bona fide meta-analysis. Whether the apparent reduction in mortality may be attributed to the mitigation of catecholamine excess is unclear.
Trial registration: PROSPERO, CRD42019130558 registered June 12, 2019.
Keywords: Beta blockers; Mortality; Sepsis; Systematic review.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
-
- Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ [Internet. 2016:i1585 [cited 2019 Mar 24]. Available from: http://www.bmj.com/lookup/doi/10.1136/bmj.i1585. - DOI - PubMed
-
- Lesur O, Delile E, Asfar P, Radermacher P. Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions. Ann Intensive Care. 2018;8(1) [cited 2019 Mar 24]. Available from: https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-0.... - DOI - PMC - PubMed
-
- Suzuki T, Suzuki Y, Okuda J, Kurazumi T, Suhara T, Ueda T, et al. Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis. J Intensive Care. 2017;5(1) [cited 2019 Mar 24]. Available from: http://jintensivecare.biomedcentral.com/articles/10.1186/s40560-017-0215-2. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
